The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland

Cancer Investigation

Volumn 25, Issue 8, 2007, Pages 742-749

  Paszko, Z ^a   Sromek, M ^a   Czetwertynska, M ^a   Skasko, E ^a   Czapczak, D ^a   Wisniewska, A ^a   Prokurat, A ^b   Chrupek, M ^b   Jagielska, A ^a   Kozlowicz Gudzinska, I ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Hereditary mutations; Medullary thyroid carcinoma; Multiple endocrine neoplasia type2 (MEN 2); Pheochromocytoma; RET gene

Indexed keywords

PROTEIN RET; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; TELERADIOTHERAPY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CARCINOMA, MEDULLARY; CHILD; CODON; FEMALE; FOLLOW-UP STUDIES; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 36849029085     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701518735     Document Type: Article

References (31)

1. Kolibaba, K.S.; Druker, B.J. Protein tyrosine kinases and cancer. Biochimica et Biophysica Acta 1997, 1333, 217-248.
2. Mulligan, L.M.; Ponder, B.A.J. Genetic basis of endocrine disease: Multiple endocrine neoplasia type 2. Journal of Clinical Endocrinology and Metabolism 1995, 80, 1989-1995.
3. Ponder, B.A.J. The phenotypes associated with retmutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Research 1999, 59, 1736-1742.
4. Arighi, E.; Borello, M.G.; Sariola, H. RET tyrosine kinase signaling in development and cancer. Cytokine & Growth Factor Reviews 2005, 16, 441-467.
5. Michiels, F.M.; Billaud, M. The RET gene in thyroid pathology. Arch Anat Cyto Path. 1998, 46, 19-30.
6. de Groot, J.W.; Links, T.P.; Plukker, J.T.; Lips, C.J.; Hofstra, R.M. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 2006, 27(5), 535-560.
7. Kodama, Y.; Asai, N.; Kawai, K.; Jijiwa, M.; Murakumo, Y.; Ichihara, M.; Takahashi, M. The RET proto-oncogene. A molecular therapeutic target in thyroid cancer. Cancer Sci. 2005, 96, 143-148.
8. de Graaff, E.; Srinivas, S.; Kilkenny, C.; D'Agati, V.; Mankoo, B.S.; Constantini, F.; Pachnis, V. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes & Development 2001, 15, 2433-2444.
9. Takahashi, M.; Buma, Y.; Iwamoto, T.; Inaguma, Y.; Ikeda, H.; Hiai, H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988, 3, 571-578.
10. Wisniewska, A.; Jagielska, A.; Paszko, Z. Proto-oncogene RET mutations in patients with medullary thyroid carcinoma. XIX Convention PTO (Polish Oncology Society) in Gdansk (Poland) 1998.
11. Wiench, M.; Scieglinska, D.; Lisowska, K.; Włoch, J.; Wygoda, Z.; Gubała, E.; Lange, D.; Krawczyk, Z.; Jarzab, B. Genetic analysis of family with Multiple Endocrine Neoplasia type 2A syndrome. Nowotwory 1998, 48, 683-691.
12. Jarzab, B.; Wiench, M.; Wojdacz, T. Receptor of RET and his role in patogenesis of papillary thyroid carcinoma. Polish Endocrinology 2004, 3, 333-341.
13. Sambrook, F.; Fritsch, E.F.; Maniatis, T. Molecular Cloning. A laboratory manual, 2 nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor 1989.
14. The Human Gene Mutation Database Cardiff (HGMD), RET, http://archive.uwcm.ac.uk/uwcm/mg/ns/1/120346.html.
15. Ceccherini, I.; Hofstra, R.M.W.; Luo, Y.; Stulp, R.P.; Barone, V.; Stelwagen, T.; Bocciardi, R.; Nijveen, H.; Bolino, A.; Seri, M.; Ronchetto, P.; Pasini, B.; Bozzano, M.; Buys, C.H.C.M.; Romeo, G. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene. 1994, 9, 3025-3029.
16. Edery, P.; Lyonnet, S.; Mulligan, L.M.; Pelet, A.; Dow, E.; Abel, L.; Holder, S.; Nihoul-Fekete, C.; Ponder, B.A.J.; Munnich, A. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367, 378-380.
17. Romeo, G.; Ronchetto, P.; Luo, Y.; Barone, V.; Ser, M.; Ceccherini, I.; Pasini, B.; Bocciardi, R.; Lerone, M.; Kaarlainen, H.; Martucciello, G. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367, (27) 377-378.
18. Carlson, K.M.; Dou, S.; Scavarda, N.; Toshima, K.; Jackson, C.E.; Well, S.A. Jr.; Goodfellow, P.J.; Donis-Keller, H. Single missence mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2 B. Proc Natl Acad Sci USA 1994, 91, 1579-83.
19. Sánchez, B.; Robledo, M.; Biarnes, J.; Saez, M.; Volpini, V.; Benitez, J.; Navarro, E.; Ruiz, A.; Antinolo, G.; and Borrego S. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain. J. Med. Genet. 1999, 36, 68-70.
20. Eng, C.; Clayton, D.; Schuffenecker, I.; Lenoir, G.; Cote, G.; Gagel, RF.; van Amstel HK.; Lips, CJ.; Nishisho, I.; Takai, SI.; et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276, 1575-9.
21. Frank-Raue, K.; Hoppner, W.; Frilling, A.; Kotzerke, J.; Dralle, H.; Haase, R.; Mann, K.; Seif, F.; et al. Mutations of the ret protooncogene in Germanmultiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 1996, 81(5), 1780-3.
22. Machens, A.; Niccoli-Sire, P.; Hoegel, J.; Frank-Raue, K.; van Vroonhoven, T.; Roecher, H.; Wahl, R.; Lamesch, P.; Raue, F.; Conte-Devolx, B.; Dralle, H. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003, 349, 1517-1525.
23. Chrupek, M.; Prokurat, A.; Kluge, P.; Jagielska, A.; Wisniewska, A.; Paszko, Z.; Krassowski, J.; Oczkowska, U.; Polnik, D.; Koúciesza, I. Value of genetic investigation (RET gene mutation) in qualification for operative treatment of herditary forms of medullary thyroid carcinoma in children. Surgery in Childhood International 2000, 8, 178-182.
24. Karga, H.J.; Karayianni, M.K.; Linos, D.A.; Tseleni, S.C.; Karaiskos, K.D.; Papapetrou, P.D. Germline mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. European Journal of Endocrinology 1998, 139, 410-415.
25. Brandi, M.; Gagel, R.; Angeli, A.; Bilezikian, J.; Beck-Peccoz, P.; Bordi, C.; Conte-Devolx, B.; Falchetti, A.; Gheri, R.; Libroia, A.; Lips, C.; Lombardi, G.; et al. Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab. 2001, 86, 5658-5671.
26. Basson, M.A.; Akbulut, S.; Watson-Johnson, J.; Simon, R.; Carroll, T.J.; Shakya, R.; Gross, I.; Martin, G.R.; Lufkin, T.; McMahon, A.P.; Wilson, P.D.; Costantini, F.D.; Mason, I.J.; Licht, J.D. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell. 2005, 8(2), 229-239.
27. Manie, S.; Santoro, M.; Fusco, A.; Billaud, M. The RET receptor: function in development and dysfunction in congenital malformation. Trends in Genetics 2001, 17, 580-589.
28. Corvi, R.; Lesuer, F.; Martinez-Alfaro, M.; Zini, M.; Decaussin, M.; Murat, A.; Romeo, G. RET rearrangements in familial papillary thyroid carcinomas. Cancer Lett. 2001, 170, 191-198.
29. Brauckhoff, M.; Gimm, O.; Hinze, R.; Ukkat, J.; Brauckhoff, K.; Dralle, H. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. Thyroid 2002, 12, 57-61.
30. Wiench, M.; Wloch, J.; Wygoda, Z.; Gubala, E.; Oczko, M.; Pawlaczek, A.; Kula, D.; Lange, D.; Jarzab, B. RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. Cancer Detection and Prevention 2004, 28, 231-236.
31. Patocs, A.; Valkusz, Z.; Igaz, P.; Balogh, K.; Toth, M.; Varga, I.; Racz, K. Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer. Clinical Genetics 2003, 63(3), 219-223.